

**Arterial Remodeling Technologies (ART) Announces CE Mark Clearance
for its Pure Bioresorbable Scaffold**

Paris, May 18, 2015 – Privately-held company Arterial Remodeling Technologies (“ART”) today announces CE Mark clearance for its next generation drug free, pure bioresorbable scaffold used to treat coronary artery disease. The CE Mark was achieved following the completion of extensive pre-clinical research, including up to three-years of follow-up, and supportive clinical results from leading coronary angioplasty centres such as the Hôpital Européen Georges Pompidou in Paris and investigators such as Dr Jean Fajadet at the Clinique Pasteur in Toulouse.

ART’s advanced bioresorbable scaffold is designed to provide a transient effective scaffolding that dismantles and relinquishes its primary mechanical function after three months, a commonly recognised requisite length of time necessary to allow the healing process to stabilise the artery. In addition the scaffold is designed to allow complete resorption of the polymer within 24 months. ART’s drug free, pure bioresorbable scaffold is particularly suitable for the treatment of larger lumen coronary artery lesions.

“Receiving the CE Mark for our Pure Bioresorbable Scaffold is a significant milestone for ART as we continue to develop this technology for the treatment of coronary artery and peripheral vascular disease,” stated Machiel van der Leest, CEO of ART. “We are very pleased with the clinical performance of the pure bioresorbable scaffold.”

Through an agreement concluded between the companies in March 2014, Terumo acquired exclusive acquisition rights for the coronary drug eluting bioresorbable scaffold technology. The pure bioresorbable CE Marked scaffold developed by ART will serve as the platform for the next generation of coronary drug eluting bioresorbable scaffolds to be developed by Terumo. Coronary artery disease is the most common type of heart disease and a leading cause of death among men and women.

Other indications, including the peripheral vascular application of the pure and drug eluting scaffolds, are being developed by Vascular Bioresorbable Technologies (“VBT”) through an exclusive license agreement to further develop ART’s platform technology.

Arterial Remodeling Technologies (www.art-stent.com), a privately-held French company, is developing bioresorbable polymer scaffolds that promote the natural remodeling of an injured artery. The Company’s technology is based on intellectual property originating from three esteemed institutions: Cleveland Clinic; French national research institute (CNRS); and Descartes University, Paris. Its investors include Bpifrance, Idinvest Partners, Turenne Capital Partners, Matignon Investissement et Gestion, Vesale Partners and Amundi Asset Management.

-end-

For further information please contact:

Dr Sophie Humbert

Chief Operating Officer, ART

E: sophie.humbert@art-stent.com